Quick Search:

is currently disabled due to reindexing of the ZORA database. Please use Advanced Search.
uzh logo
Browse by:

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-40788

Borsig, L (2010). Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thrombosis Research, 125(Suppl2):S66-S71.

Accepted Version


Heparin is commonly used for prevention or treatment of cancer-associated thromboembolism. Recent clinical evidence indicates that heparin, and low-molecular weight heparin improves survival of cancer patients. Experimental evidence from various animal models consistently supports the ability of heparin to attenuate metastasis. Heparin, apart from its anticoagulant activity contains a variety of biological activities possibly affecting cancer progression, including: inhibition of heparanase, blocking of P- and L-selectin mediated cell adhesion, and inhibition of angiogenesis. The delineation of antimetastatic activity of heparin is in the focus of several ongoing investigations. This review summarizes the current experimental evidence on the biology of heparin as a potential treatment cancer progression.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology
DDC:570 Life sciences; biology
Date:15 April 2010
Deposited On:14 Jan 2011 15:32
Last Modified:20 Oct 2012 15:26
Publisher DOI:10.1016/S0049-3848(10)70017-7
PubMed ID:20434009
Citations:Google Scholar™
Scopus®. Citation Count: 25

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page